Novotech具有為生技業者完美交付全球專案的豐富經驗和專業實力 Novotech收購美國CRO，擴大全球專業布局——閱讀完整報導 我們的營業地區 我們的營業地區 Australia 先進的醫療和研究基礎設施 針對臨床試驗支出，可獲得高達 43.5%的政府費用返還 簡單快速的監管路徑 點擊查看更多相關資訊 歐洲 歐洲擁有蓬勃發展的生物科技產業，以及立基於歐洲的 CRO EastHORN 加入 Novotech，改善了我們與該客戶群的接觸管道。 由於終端市場的商業規模及龐大患者族群的可用性 (尤其是在中歐和東歐)，使得歐洲成為一個極具吸引力的臨床研發區域。 歐洲一直是生物相似性藥品監管的領導者，並且許多此類試驗皆於歐洲進行。 點擊查看更多相關資訊 Greater China Very large, homogenous population Strong focus of NMPA (previously CFDA) on shortening regulatory timelines Largest clinical trial hub in Asia, with over 17,000 active investigators 點擊查看更多相關資訊 India Large treatment-naïve population High disease population load The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements About 1,800 investigators have participated on a minimum of 5 studies 點擊查看更多相關資訊 Malaysia Multiethnic Asian population Streamlined regulatory system and Strong govt. support Quick start-up timelines Low patient costs and IRB fees 點擊查看更多相關資訊 New Zealand High-quality research, facilities and equipment Fast set-up and approval times Sponsor can claim R&D cash refund 點擊查看更多相關資訊 Philippines Large treatment-naïve population Low costs Overall good level of English 點擊查看更多相關資訊 Singapore Multiethnic Asian population Regional clinical research hub Efficient regulatory process and good infrastructure 點擊查看更多相關資訊 South Korea Homogenous and concentrated population High quality medical services and excellent infrastructure The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018 點擊查看更多相關資訊 Thailand Large homogenous population High prevalence of communicable diseases Efficient regulatory system Low operational cost 點擊查看更多相關資訊 United States of America Following the acquisition and integration of a long standing full-service CRO partner, Novotech now provides services across the United States" 點擊查看更多相關資訊
全域
中國
